Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Go back to Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration| (NASDAQ: OCGN) | Delayed: 1.38 +0.09 (6.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.29 | 52 Week High | $ | |||
| Open | $1.28 | 52 Week Low | $ | |||
| Day High | $1.43 | P/E | N/A | |||
| Day Low | $1.28 | EPS | $ | |||
| Volume | 8,143,638 | |||||
